Forescout Launches Forescout Frontline to Help Organizations Tackle Ransomware and Real Time Threats
Forescout Technologies, the leader in automated cybersecurity, today announced the launch of Forescout Frontline, a new threat hunting service utilizing a team of highly-trained cybersecurity analysts to support cybersecurity teams by proactively identifying risks, enabling accelerated incident response, and maturing security posture. Forescout is offering this complimentary service for organizations that lack the internal resources and visibility to defend themselves from cybersecurity attacks, including ransomware and advanced persistent threats (APT).
“Cybersecurity attacks are on the rise. Simultaneously, cybersecurity teams are perennially understaffed and under resourced. This has created a perfect storm,” said Shawn Taylor, vice president of threat defense. “Organizations are under immense pressure to cope with the scale and speed of attacks and the havoc caused by the adversaries. Forescout is launching this new service to help organizations defend against attacks by providing a complete and holistic view of their assets.”
Many organizations use multiple security tools across multiple teams to help identify threats and risks. However, insights may be limited due to siloed views of IT, IoT, IoMT or OT assets. Typically, a variety of these asset types exist across an organization’s digital terrain and are often interconnected, which means cybersecurity risk must be identified and tackled holistically.
Delivered by Forescout Frontline analysts, the Threat Hunting and Risk Identification Service overcomes staffing resources and asset visibility challenges to uncover threats and identify risks that may otherwise remain undiscovered. Forescout Frontline will help organizations:
- Discover, validate and prioritize a wide variety of cyber threats and vulnerabilities across all assets, including IT, IoT, IoMT and OT
- Analyze the context and risk associated with all findings
- Leverage the comprehensive insights to develop effective risk mitigation and remediation strategies
A State of Florida Agency, which supports several key Florida departments, engaged Forescout Frontline to understand each instance of Log4j, a zero-day vulnerability in a popular Java logging framework, across the organization’s 220 sites in 16 diverse divisions. In less than a day and a half, Forescout Frontline delivered insights into thousands of assets with vulnerabilities such as Log4j and Windows-based PrintNightmare. Additionally, hundreds of Critical CVSS-rated vulnerabilities affecting infrastructure devices such as switches and routers were found. Finally, actionable intelligence concerning critical embedded IoT TCP-IP stack-based instances such as NUCLEUS: 13 and RIPPLE 20, insecure communications, and other risks were also discovered. Leveraging this free service shrunk time to mitigation and remediation of these security gaps and improved overall security posture.
“When Log4J broke, we knew it was a critical issue, but we lacked a full picture of the risk within our extended enterprise. The [Forescout threat hunting] report was way more thorough than I expected, with in-depth information and actionable intelligence. Not just on Log4j but on other critical vulnerabilities as well, and not just in general terms but exactly where they exist in our environment.” – Information Security Manager, State of Florida Agency
Forescout Frontline levels the cybersecurity playing field by operationalizing the vulnerability research and threat intelligence produced by Forescout’s Vedere Labs and enhancing it with the Forescout Continuum Platform to provide threat hunting services across multiple dimensions. Forescout Frontline analysts include former public sector and private sector threat hunters with training in threat detection and incident response.
Forescout Technologies, Inc. delivers automated cybersecurity across the digital terrain, maintaining continuous alignment of customers’ security frameworks with their digital realities, including all asset types – IT, OT, IoT, IoMT. The Forescout Continuum Platform provides complete asset visibility, continuous compliance, network segmentation and a strong foundation for Zero Trust. For more than 20 years, Fortune 100 organizations and government agencies have trusted Forescout to provide automated cybersecurity at scale. Forescout arms customers with data-powered intelligence to accurately detect risks and quickly remediate cyberthreats without disruption of critical business assets.
Managing cyber risk, together.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Media Relations Contact:
Forescout Technologies, Inc.
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Teva Announces Promising Interim Results From Its Study PEARL, About the Impact of AJOVY ® (fremanezumab)24.6.2022 18:54:00 CEST | Press release
Teva Pharmaceuticals Europe B.V. today announces promising interim results from its Pan-European Real World study (PEARL), presented for the first time at the European Academy of Neurology (EAN) Congress in Vienna, Austria. The two-year Pan-European Real World (PEARL) prospective, observational study of AJOVY® (fremanezumab), looks at its effectiveness in patients with chronic migraine or episodic migraine, and is an ongoing study sponsored by Teva Pharmaceuticals Europe BV.1 These findings further offer insight into the treatment of migraine in real-world clinical practice. The interim findings were presented by Faisal Mohammad Amin, Associate Professor of Neurology at the University of Copenhagen, Denmark. Out of the total planned 1100 patients in PEARL, 389 patients are included in the interim analysis presented. These findings show that 54.7% of patients in the study had their monthly-migraine-days reduced by 50% or more, over the six-month period from the start of treatment. Addit
Brigade-M3 European Acquisition Corp. 2021 Annual Report24.6.2022 16:59:00 CEST | Press release
Brigade-M3 European Acquisition Corp. (the “Company”), a special purpose acquisition company that was incorporated on 21 April 2021 under the laws of the Cayman Islands as an exempted company with limited liability and is listed on Euronext Amsterdam, today published its annual report for the period 21 April 2021 to 31 December 2021. The full report can be downloaded from the Company’s website via the following link: https://www.brigadem3eac.com/documents IMPORTANT INFORMATION This press release contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. DISCLAIMER This announcement is not for distribution or release, directly or indirectly, and should not be distributed in or sent into, the United States, Australia, Canada, Japan, the Cayman Islands or South Africa or any other jurisdiction in which such distribution or release would be unlawful or would require registration or other measures. This announcement does n
PUMA Kicks Off Its Largest Web3 Collaboration To Date, with 10KTF Shop24.6.2022 16:41:00 CEST | Press release
PUMA has entered New Tokyo, the virtual city 10KTF calls home. The shop is known for its streetwear offerings and is owned by Wagmi-san, a digital artisan whose collections and NFT community recently welcomed the global sports brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220624005314/en/ PUMA Kicks Off Its Largest Web3 Collaboration To Date, with 10KTF Shop PUMA has entered New Tokyo, the virtual city 10KTF calls home. The shop is known for its streetwear offerings and is owned by Wagmi-san, a digital artisan whose collections and NFT community recently welcomed the global sports brand. (Photo: Business Wire) News of the partnership was shared at an event hosted by 10KTF last night in New York. Their event was one of many hosted during the week of NFT.NYC, a conference attended by crypto industry professionals, traders, and other web3 enthusiasts. The official announcement confirms weeks of speculation after PUMA tw
Suzano outlines ESG milestone achievements and commitments at second annual ESG call24.6.2022 16:14:00 CEST | Press release
Suzano, the world’s largest hardwood pulp producer, today held its second annual ESG Call centered around its ambition to be a ‘regenerative company for a regenerative society’. Today’s ESG Call spotlighted measurable progress and ambitions across three core areas of action: climate change, biodiversity and social development. On Climate Change, the ACT initiative of the French Government and CDP scored Suzano ahead of its pulp and paper industry peers in virtually every metric. In 2021, Suzano brought forward its target for removing 40 million tons of carbon dioxide from the atmosphere from 2030 to 2025 which is being achieved through improvements to its industrial processes, such as systematically replacing the use of fossil fuels at its industrial plants with biomass, and through conversion of degraded land. As part of the company’s social commitments, Suzano launched a target in 2020 to lift 200,000 people out of poverty. This is more than pertinent, given that in Brazil, 10% of th
Kyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA ® ▼ (burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)24.6.2022 15:38:00 CEST | Press release
Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended that CRYSVITA® (burosumab) be approved for the treatment of FGF23-related hypophosphataemia in Tumour-Induced Osteomalacia (TIO) associated with phosphaturic mesenchymal tumours (PMTs) that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.1 CRYSVITA is also already licensed for use in the rare disease X-Linked Hypophosphataemia (XLH), for children and adolescents between 1 and 17 years of age with radiographic evidence of bone disease, and in adults.2 Also known as oncogenic osteomalacia, TIO is an acquired disorder caused by typically small, slow-growing, benign PMTs.3,4 It is a rare condition with less than 1000 cases reported in the medical literature,4 which mainly affects adults and with a mean onset age of 40 – 45 years.3,5 TIO is associated with p